Category: Press Release

BIOVECTRA Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund

Posted on by BIOVECTRA
A group of nine people in formal attire posing in front of a BioVectra display inside a warehouse environment.

BIOVECTRA Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund — Prime Minister Justin Trudeau visits BIOVECTRA to announce Government of Canada investment in Atlantic Canadian CDMO and high-skilled jobs creation in the region — Charlottetown, Prince Edward Island, Canada (March 4, 2019) – […]

Read More…

BIOVECTRA wins BIOTECanada’s Gold Leaf Award for Company of the Year!

Posted on by BIOVECTRA
Two people in suits stand indoors, smiling. One person holds a plaque. Background is plain with a dark curtain on the right.

CANADIAN BIOTECH INDUSTRY RECOGNIZES TOP PERFORMERS DURING GLOBAL BIOTECH WEEK September 26, 2018 [OTTAWA] – BIOTECanada is pleased to announce the 2018 winners of the Gold Leaf Awards which annually highlight innovation and entrepreneurship within the Canadian biotechnology industry. This national celebration of the Canadian industry represents an outstanding collection of companies and individuals who […]

Read More…

BIOVECTRA and TUBE Biopharmaceuticals Sign Exclusive License for Microbial Fermentation Technology to Manufacture Tubulysins

Posted on by BIOVECTRA
Blue text logo displaying "Tube Pharma" on a white background, likely representing a pharmaceutical company or brand identity. No people or landmarks present.

BIOVECTRA and TUBE Biopharmaceuticals Sign Exclusive License for Microbial Fermentation Technology to Manufacture Tubulysins 16/07/18 – CHARLOTTETOWN, Prince Edward Island, Canada – Today, BIOVECTRA Inc., a global Contract Development and Manufacturing Organization (CDMO) with microbial fermentation and synthesis capabilities with high containment, and TUBE Biopharmaceuticals GmbH, an Austrian biotech company active in the research field […]

Read More…

Windsor Expansion Helps BIOVECTRA Meet Global Market Demand

Posted on by BIOVECTRA
Industrial building in snowy setting with BioVectra sign featuring address 24 Ivey Lane. A person is approaching the entrance.

Windsor Expansion Helps BIOVECTRA Meet Global Market Demand Extensive facility renovation, new equipment, assists life sciences firm in creating jobs, growing regional economy April 12, 2018 – Windsor, NS – Atlantic Canada Opportunities Agency Canada is a country of innovators. Curiosity, creativity and a collaborative spirit are what lead to the kinds of innovations and […]

Read More…

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors